Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 34 for:    denosumab AND breast cancer
Previous Study | Return to List | Next Study

Denosumab for Breast Cancer With Bone Mets

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01952054
Recruitment Status : Terminated
First Posted : September 27, 2013
Results First Posted : November 22, 2019
Last Update Posted : November 22, 2019
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:

The goal of this clinical research study is to learn if denosumab in combination with a hormonal drug can help lower the number of circulating tumor cells (CTCs) in patients with breast cancer that has spread to the bone. The safety of this combination will also be studied.

This is an investigational study. Denosumab is FDA approved and commercially available to prevent bone-related events caused by breast cancer that has spread to the bone. Using denosumab to lower CTCs in patients with breast cancer that has spread to the bone is investigational.

You may have the option of continuing denosumab after the study ends.

Up to 35 patients will take part in this study. All will be enrolled at MD Anderson.


Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Denosumab Phase 2

Detailed Description:

Study Drug Administration:

If you are found to be eligible to take part in this study, you will receive denosumab through a needle under your skin on Day 1 of each 28-day study cycle.

Starting on Day 1 of week 4, you will also begin taking a hormonal drug. The study doctor will choose the hormonal drug you receive based on your previous hormonal therapy for breast cancer. The study doctor will give you instructions for taking your hormonal drug.

Study Visits:

On Day 1 of week 4:

  • You will have a physical exam
  • Blood (about 3 tablespoons) will be drawn for routine tests
  • Blood (about 5 teaspoons) will be drawn for CTC testing and to check your immune system.
  • Urine will be collected to test for a biomarker that is used to measure the rate of bone breakdown.
  • If the study doctor thinks it is needed, you will have a PET scan, a bone scan, or an MRI to check the status of the disease.

On Day 1 of Cycle 2 and Cycle 3, blood (about 1 teaspoon) will be drawn for routine tests.

Length of Study:

You may receive the denosumab and hormonal therapy combination for up to 13 weeks. You will be taken off study if the disease gets worse or intolerable side effects occur.

End of Study Visit:

After your last dose of the study drug, the following tests and procedures will be performed:

  • You will have a physical exam.
  • Blood (about 3 tablespoons) will be drawn for routine tests.
  • Blood (about 5 teaspoons) will be drawn for CTC testing and to check your immune system.
  • Urine will be collected to test for a biomarker that is used to measure the rate of bone breakdown.
  • If the study doctor thinks it is needed, you will have a PET scan, a bone scan, or an MRI to check the status of the disease.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis
Actual Study Start Date : February 9, 2015
Actual Primary Completion Date : October 10, 2018
Actual Study Completion Date : October 10, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Denosumab

Arm Intervention/treatment
Experimental: Denosumab
Participants receive a single subcutaneous (SC) administration of Denosumab 120 mg every 4 weeks (+/- 5days). Starting week 5, in addition to receiving Denosumab every 4 weeks, participants receive a hormonal agent chosen by each physician, excluding the agent that participants received at adjuvant therapy setting.
Drug: Denosumab
120 mg subcutaneously on Day 1 of every 28 day cycle.
Other Names:
  • AMG 162
  • Prolia




Primary Outcome Measures :
  1. The Effect of Denosumab in Reducing Circulating Tumor Cells (CTCs) Among Breast Cancer Patients With Bone Metastases. [ Time Frame: Baseline, week 4 ]
    The difference in number of CTCs in 7.5 ml whole blood from baseline to week4. CTC reduction from baseline to week4 is statistically analyzed using the two-sided paired t-test with the significance level of 0.05.


Secondary Outcome Measures :
  1. The Changes of Epithelial-mesenchymal Transition (EMT) in CTCs [ Time Frame: Baseline, week 4 ]
    The change in Her2, Muc-1, GA733-2 (EpCAM), Twist, Akt, PI3K and ALDH-1 in CTCs after 1 st cycle of treatment with denosumab.

  2. The Changes in Urine N-telopeptide Level [ Time Frame: Baseline up to week 13 ]
    The collection urine is performed at baseline, at week4 and the end of 3rd cycle (week13) to evaluate the level of N-telopeptide.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients have histological confirmation of breast carcinoma.
  2. Patients have progressive metastatic disease with predominantly bone metastasis with 1 or more lesions and at least 1 bone lesion has pathological confirmation, have not been treated or have been treated with any prior therapies (including bisphosphonate treatment and/or radiation therapy). Patients can have soft tissue involvement (Lymph node and skin) and/or metastatic lesions at major organ sites (i.e. lung, liver, etc).
  3. Patients have positive ER expression in the primary tumor site by IHC (defined as >/=10%) (PR status is not required)
  4. Adequate hematologic function: 1)Absolute neutrophil count (ANC) >/= 1.0 x 10^9/L, 2) Platelet count >/= 50 x 10^9/L, 3) Hemoglobin >/= 9.0 g/dL
  5. Adequate cardiac function (LVEF >/= 45%) if patient has known cardiac dysfunction history
  6. Adequate Renal function: Calculated creatinine clearance >30 ml/min
  7. Adequate Hepatic function: 1) Aspartate aminotransferase (AST) </= 2.5 x ULN; 2) Alanine aminotransferase (ALT) </= 2.5 x ULN; 3) Alkaline phosphatase (Alp) </= 2.5 x ULN; 4) Total bilirubin </= 2.0 x ULN
  8. Serum calcium or albumin-adjusted serum calcium >/=2.0mmol/L (8.0mg/dL) and </= 2.9 mmol/L (11.5mg/dL)
  9. Patients have ability and willingness to sign written informed consent.
  10. Patients are 18 years of age or older.
  11. Female patients of childbearing potential (A female not free from menses > 2 years or not surgically sterilized) must be willing to use highly effective contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study. Highly effective contraception, defined as male condom with spermicide, diaphragm with spermicide, intra-uterine device. Highly effective contraception must be used by both sexes during the study and must be continued for 5 months after the last dose of denosumab.
  12. Female patients of childbearing potential must have negative serum pregnancy test </= 21 days prior to starting study treatment.
  13. Patients have CTC >/=3.

Exclusion Criteria:

  1. Patients have known sensitivity to any of the products to be administered during the study (e.g., mammalian derived products, calcium, or vitamin D).
  2. Patients receiving concurrent anti-cancer therapy (chemotherapy, immunotherapy, radiation therapy and biological therapy) while taking study medication. However, patients receiving CDK4/6 inhibitor or mTOR inhibitor as a standard of care while on study is permitted.
  3. Patients with metastatic sites that requires chemotherapy.
  4. Patients with active infection and requiring IV or oral antibiotics.
  5. Patients with concurrent disease or condition that would make them inappropriate for study participation, or any serious medical disorder that would interfere with patients' safety.
  6. Patients have HER2-positive breast carcinoma (IHC staining more than 3+ or HER2 gene amplification by FISH)
  7. Patient is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment.
  8. Patient is of child bearing potential and is not willing to use, in combination with her partner, two highly effective methods of contraception or abstinence during treatment and for 5 months after the end of treatment.
  9. Male patients.
  10. Patients have prior history or current evidence of osteonecrosis/osteomyelitis of the jaw.
  11. Patients have active dental or jaw condition which requires oral surgery, including tooth extraction.
  12. Patients have non healed dental/oral surgery, including tooth extraction.
  13. Patients planned invasive dental procedures.
  14. Patients experiencing a visceral crisis including severe organ dysfunction as assessed by > Gr 2 symptomatic toxicities, laboratory studies, and/ or rapid progression of disease originating from visceral metastasis.
  15. Patients that have received the study medication (Xgeva/Prolia).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01952054


Locations
Layout table for location information
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Amgen
Investigators
Layout table for investigator information
Principal Investigator: Naoto Ueno, MD, PHD M.D. Anderson Cancer Center
  Study Documents (Full-Text)

Documents provided by M.D. Anderson Cancer Center:
Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT01952054    
Other Study ID Numbers: 2013-0007
NCI-2014-01273 ( Registry Identifier: NCI CTRP )
First Posted: September 27, 2013    Key Record Dates
Results First Posted: November 22, 2019
Last Update Posted: November 22, 2019
Last Verified: November 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by M.D. Anderson Cancer Center:
Breast cancer
Breast carcinoma
Bone metastasis
Cancer that has spread to the bone
Denosumab
AMG 162
Prolia
Hormonal agent
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Denosumab
Bone Density Conservation Agents
Physiological Effects of Drugs